As of 14 Oct 2026, Korsana has raised $150M across 1 verified round on record; latest: $150 million Series A led by TCGX and Wellington Management, announced 18 Feb 2026.
Korsana develops advanced therapeutics aimed at treating neurodegenerative diseases, particularly focusing on Alzheimer's disease.
2 sources
The $175 million figure is combined funding: the $25 million seed plus the $150 million Series A; the round itself is $150 million.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2026-02-18 | TCGX, Wellington Management | No recent discussion |
2 sources [ VERIFIED · CORRECTED ] read against 2 sources
The $175 million figure is combined funding: the $25 million seed plus the $150 million Series A; the round itself is $150 million. | ||||